Results 61 to 70 of about 225,391 (165)

PDGFRα+DPP4+ Fibroblasts‐Macrophage Crosstalk Induces Orbital Fibrosis in Treatment‐Resistant Thyroid Eye Disease via the GAS6‐AXL Pathway

open access: yesAdvanced Science, Volume 12, Issue 45, December 4, 2025.
This study elucidates macrophage‐induced orbital fibrosis in TED via the GAS6‐AXL pathway, a treatment‐resistant disorder lacking non‐surgical therapies. Using a novel patient cell‐derived orthotopic animal model of orbital fibrosis for TED, we repurpose an existing fibrosis therapy, addressing the absence of stable models and offering a potential ...
Lu Cheng   +14 more
wiley   +1 more source

Thyroid-associated Ophthalmopathy

open access: yes, 2017
Thyroid-associated ophthalmopathy is the most frequent extrathyroidal involvement of Graves’ disease but it sometimes occurs in euthyroid or hypothyroid patients.
Kaan Gündüz, Esra Şahlı
core   +1 more source

Development and psychometric properties of the Thai Graves’ ophthalmopathy quality of life (GO-QOL) questionnaire

open access: yesJournal of Patient-Reported Outcomes, 2019
Purpose To develop and assess the psychometric properties of the Thai version of the Graves’ Ophthalmopathy Quality of Life (GO-QOL) questionnaire. Background Graves’ ophthalmopathy (GO) is a chronic condition that causes negative self-image and impaired
Mingkwan Lumyongsatien   +8 more
doaj   +1 more source

Epidemiology and prevention of Graves' ophthalmopathy

open access: yes, 2002
Graves' ophthalmopathy is clinically relevant in approximately 50% of patients with Graves' disease, severe forms affecting 3%-5% of patients. Two age peaks of incidence are observed in the fifth and seventh decades of life, with slight differences ...
Wiersinga, Wilmar M.   +2 more
core   +1 more source

Orbital gallium-67 scintigraphy in Graves' ophthalmopathy

open access: yes, 2002
Assessment of orbital disease activity in patients with Graves' ophthalmopathy is important in planning the therapeutic approach. In this study, orbital uptake of gallium-67 citrate (Ga-67) was evaluated in 46 consecutive patients demonstrating active or
Arslan, M   +7 more
core   +1 more source

Endoscopic orbital decompression in Graves ophthalmopathy - Case report

open access: yes, 2018
Graves ophthalmopathy, an autoimmune disease, associated with hypermetabolism, enlargement of the thyroid gland and exophthalmia are the most frequent expressions of Graves’ disease, which often require surgical treatment.
Tatiana Decuseara   +5 more
core   +1 more source

Increased percentage of L-selectin+ and ICAM-1+ peripheral blood CD4+/CD8+ T cells in active Graves' ophthalmopathy.

open access: yesFolia Histochemica et Cytobiologica, 2009
The purpose of the study was to evaluate the percentage of CD4+/CD8+ peripheral T cells expressing CD62L+ and CD54+ in patients with Graves' disease and to assess if these estimations could be helpful as markers of active ophthalmopathy.
Alina Bakunowicz-Lazarczyk   +4 more
doaj   +1 more source

Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy

open access: yes, 2017
Graves' ophthalmopathy is defined as autoimmune inflammation of extraocular muscles and orbital fat or connective tissue, usually in patients with Graves' disease.
Wiersinga, Wilmar M.
core   +1 more source

The Application of Temperature Measurement of the Eyes by Digital Infrared Thermal Imaging as a Prognostic Factor of Methylprednisolone Pulse Therapy for Graves' Ophthalmopathy

open access: yes, 2011
Purpose: Graves' ophthalmopathy (GO) involves autoimmune process resulting in proptosis, congestion, oedema and diplopia. Werner's NOSPECS classification and clinical activity score (CAS) of GO cannot objectively describe the inflammatory status. Digital
施翔蓉;李弘元;蕭永廉;張天鈞   +1 more
core   +1 more source

HLA-DR4 associated response to corticosteroids in Graves' ophthalmopathy patients

open access: yes, 1990
Fifty-seven patients with severe Graves' ophthalmopathy were treated with corticosteroids. Therapeutic outcome was assessed according to predetermined criteria as response (n = 37) or non-response (n = 20) to therapy.
D'Amaro, J.   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy